

1 **NET-prism enables RNA polymerase-dedicated transcriptional**
2 **interrogation at nucleotide resolution**

3

4 Constantine Mylonas¹ and Peter Tessarz^{1,2,3}

5

6

7 1 - Max Planck Institute for Biology of Ageing, Joseph-Stelzmann-Str. 9b, 50931
8 Cologne, Germany

9 2 - Cologne Excellence Cluster on Cellular Stress Responses in Ageing Associated
10 Diseases (CECAD), University of Cologne, Joseph-Stelzmann-Strasse 26, 50931
11 Cologne, Germany

12 3 - corresponding author: ptessarz@age.mpg.de

13

14

15

16

17 **The advent of quantitative approaches that enable interrogation of transcription**
18 **at single nucleotide resolution has allowed a novel understanding of**
19 **transcriptional regulation previously undefined. To better map transcription**
20 **genome-wide at base pair resolution and with transcription/elongation factor**
21 **dependency we developed an adapted NET-seq protocol called NET-prism (Native**
22 **Elongating Transcription by Polymerase-Regulated Immunoprecipitants in the**
23 **Mammalian genome). NET-prism introduces an immunoprecipitation to capture**
24 **RNA Pol II – associated proteins, which reveals the interaction of these proteins**
25 **with active RNA Pol II. Application of NET-prism on different Pol II subunits (Pol II**
26 **S2ph, Pol II S5ph), elongation factors (Spt6, Ssrp1), and components of the pre-**
27 **initiation complex (PIC) (TFIID, TBP, and Mediator) reveals diverse Pol II signals,**
28 **at a single nucleotide resolution, with regards to directionality and intensity over**
29 **promoters, splice sites, and enhancers/super-enhancers. NET-prism will be**
30 **broadly applicable as it exposes transcription factor/Pol II dependent topographic**
31 **specificity and thus, a new degree of regulatory complexity.**

32

33 Approaches that precisely map the position of RNA Pol II at a high resolution are
34 considered the cradle of transcriptional cartography as they provide a deeper insight
35 into transcriptional regulatory mechanisms¹⁻⁶. The human NET-seq protocol
36 quantitatively purifies Pol II in the presence of a strong Pol II inhibitor hence omitting the
37 utilisation of an antibody². Although, it successfully maps the 3'end of nascent RNA to
38 reveal the strand-specific position of Pol II with single nucleotide resolution, it cannot
39 distinguish between different Pol II variants or specific protein-dependent transcriptional
40 processes. On the other hand, the mammalian NET-seq protocol (mNET-seq) uses an
41 IP to capture the nascent RNA produced by different C-terminal domain (CTD)
42 phosphorylated forms of Pol II⁷. However, mNET-seq relies on the release of Pol II
43 complexes from chromatin via digestion with micrococcal nuclease (MNase); a potent

44 nuclease that digests both DNA and nascent RNA. Consequently, short nascent RNA
45 fragments may not be incorporated into the library.

46 Here we describe an approach (NET-prism) to capture nascent RNA transcripts
47 generated by different Pol II variants and transcription/elongation factors associated
48 with active Pol II. Nuclei are extracted in the presence of a strong inhibitor for Pol II (α -
49 amanitin) to prevent run-on of the polymerase. Subsequently, nuclei are treated with
50 DNase I to solubilise chromatin and promote release of the RNA Pol II complex while
51 keeping the nascent RNA intact (**Supplementary Fig. 1a, b**). An antibody is then used
52 to immunoprecipitate either differentially phosphorylated RNA Pol II variants or proteins
53 bound to RNA Pol II. The successfully purified nascent RNA is later parsed into the
54 NET-seq library preparation as previously described ². The detailed protocol is outlined
55 in **Figure 1a** and is also available in the Methods section.

56

57 **Results**


58 **Nascent RNA transcripts by differently phosphorylated Pol II variants**

59 Initially, we applied NET-prism to map the strand-specific location of two differently
60 phosphorylated Pol II variants (Pol II S2ph, and Pol II S5ph) at single nucleotide
61 resolution. Over protein-coding genes, the Pol II S2ph variant was found to be highly
62 enriched close to the TSS (Transcription Start Site), and after the TES (Transcription
63 Termination Site), whereas the Pol II S5ph variant exhibited similar distribution to total
64 Pol II as assessed by NET-seq (**Fig. 1b,c**). Similar Pol II occupancies were also

65 detected over long non-coding RNAs (**Supplementary Fig. 2**). Very high correlations
66 were observed between the different replicates ($R = 0.99$; Pol II S5ph, $R = 0.98$; Pol
67 S2ph – **Supplementary Fig. 3a**) confirming the robustness and reproducibility of NET-
68 prism. Moreover, the validity of the data and its robustness was confirmed by obtaining
69 relatively high correlations between ChIP-seq and NET-prism ($R = 0.75$; Pol II S5ph, R
70 $= 0.69$; Pol S2ph – **Supplementary Fig. 3b**). To further assess the density distribution
71 of both Pol II variants, we calculated the travelling ratios (Pol II density over proximal
72 promoter versus gene body), and termination indices (Pol II density over termination
73 versus gene body). No significant difference was observed between the travelling ratio
74 of total Pol II (NET-seq) and Pol II S5ph (NET-prism), as opposed to Pol II S2ph ($p < 10^{-16}$).
75 Conversely, Pol II S5ph displayed a significantly lower termination index whereas
76 the Pol II S2ph exhibited the highest, confirming enrichment of Pol II S2ph over
77 promoters and termination sites and that of Pol II S5ph over promoters and gene body
78 regions (**Fig. 1d**).

79

80



82 **Figure 1:** NET-prism enables polymerase-specific transcriptional interrogation at a high
83 resolution. **(a)** NET-prism protocol overview. **(b)** Metaplot profiles for total Pol II (ChIP-
84 seq & NET-seq) and Pol II S2ph / Pol II S5ph (ChIP-seq & NET-prism) over the TSS
85 and TES of protein-coding genes (n = 6,107). No smoothing has been applied. **(c)** Pol II
86 density (Total Pol II, Pol II S2ph, Pol II S5ph), assessed either by ChIP-seq or NET-
87 seq/prism, over a single gene (*Egr1*). Black = ChIP-seq density, Blue = Sense
88 transcription (NET-seq/prism), Red = Anti-sense transcription (NET-seq/prism). **(d)**
89 Boxplot comparison of the travelling ratios and termination indices for total Pol II, Pol II
90 S2ph, and Pol II S5ph assessed via NET-seq/prism. Significance was tested via the
91 Wilcoxon rank test (** $p < 2.2e^{-16}$, n.s. = non-significant).

92

93

94 **Transcription factor – Pol II dependent nascent transcription**

95 Given the high concordance between ChIP-seq and NET-prism for both RNA Pol II
96 variants, we next applied NET-prism on the elongation factors Spt6, and Ssrp1 (subunit
97 of the FACT heterodimer), as well as on Transcription factor IID (TFIID), TATA-binding
98 box protein (TBP), and Mediator (Med) with the latter serving as fundamental
99 components of the pre-initiation complex (PIC). The data were highly reproducible
100 among replicates (**Supplementary Fig. 4a**) and exhibited diverse levels of correlations
101 over promoter regions (**Supplementary Fig. 4b**) indicating that different TFs establish
102 unique Pol II footprints. Indeed, aligned and averaged NET-prism profiles over the TSS
103 expose diversity in transcriptional initiation and elongation, suggesting that TF binding
104 specificity directly affects RNA Pol II travelling. IPs for elongation factors Spt6 and
105 Ssrp1 show strong and broad enrichment of the Pol II complex reminiscent of Pol II
106 S2ph and Pol II S5ph distribution, respectively. Conversely, TFIID, and TBP IPs display
107 sharper Pol II signals centred around the TSS (**Fig. 2a**). Similar Pol II patterns were also
108 confirmed at a single gene level (**Fig. 2b**).

109 Nascent RNA transcripts upstream of the TSS are too short to produce mappable
110 sequencing reads as the minimum read length is ~18 nt for unique alignment to the
111 mammalian genome. Moreover, formation of the pre-initiation complex (PIC) at
112 promoter regions occurs before nascent RNA synthesis. Therefore, in order to
113 characterise Pol II distribution over the PIC we coined the “Reverse travelling ratio”
114 which is defined as the density of elongating divergent Pol II versus the density of
115 divergent Pol II at initiation (**Fig. 2c** – schematic diagram). Interrogation of the regions
116 with the highest Pol II density (n = 823) revealed a confinement of anti-sense Pol II

117 (lower reverse travelling ratios), bound by either TFIID or TBP, adjacent to TSS, thus
118 confirming their role in pre-initiation. In addition, Pol II bound by either Spt6 or Ssrp1
119 exhibit higher reverse travelling ratios indicative of a broader anti-sense Pol II
120 distribution (**Fig. 2c**). This is in agreement with ChIP-seq densities for both elongation
121 factors^{8,9}.




122 To test more systematically whether different NET-prism profiles generate exclusive Pol
123 II distributions with regard to broadness and directionality, we calculated the travelling
124 ratio in the sense direction for all the above NET-prism libraries (**Supplementary Fig.**
125 **4c**). Similarly, to the reverse travelling ratio, we confirmed the notion of a restrained Pol
126 II at the TSS that is exclusively bound by TFIID and TBP, as opposed to Spt6 and Ssrp1
127 that support an involvement in transcriptional elongation. Surprisingly, both the reverse
128 and normal travelling ratios expose a closer association of Spt6 to Pol II S2ph whereas
129 that of Ssrp1 to Pol II S5ph. Corroborative evidence supporting this association arises
130 from structural studies where the SH2 domain of Spt6 displays high affinity to Pol II
131 S2ph^{10,11}.

132 Out of all the NET-prism libraries that we generated, Med IP displayed the lowest Pol II
133 density over protein-coding promoters despite its sequencing depth degree (137 million
134 total reads, 49 million uniquely aligned). One likely explanation might be that the
135 nascent RNA obtained by IP is strongly dependent on the binding affinity of each TF to
136 RNA Pol II, explaining the lower Pol II read count over promoter regions for these
137 specific IPs. Indeed, the crystal structures of human and yeast PIC reveal that TBP does
138 not directly contact RNA Pol II, whereas the binding surface between Med14 and RNA
139 Pol II is limited (**Supplementary Fig. 5a,b**). To confirm this, we interrogated the total

140 Pol II protein interactome via Mass spectrometry using the same extraction conditions
141 as NET-prism. Positive (Supt5, Supt6, FACT, Paf1) and negative (NELF) elongation
142 factors as well as splicing (Srsf5, Srsf6) and TFIID (Taf10, Taf15) components
143 displayed a significant association with Pol II (**Supplementary Fig. 5c**). Neither TBP
144 nor Mediator components were observed in the dataset suggesting either absent or
145 weak interactions. Nevertheless, Pol II occupancy facilitated by Med is abundant over
146 lncRNAs, snRNAs, and snoRNAs (**Supplementary Fig. 5d,e**) whereas the high
147 replicate reproducibility (**Supplementary Fig. 5f**) confirms the robustness of the NET-
148 prism protocol.

149

150



151

152

153 **Figure 2:** NET-prism application on polymerase-bound transcription factors. **(a)**
154 Metaplot profiles and heatmaps over protein-coding genes (n =4,314) for polymerase
155 associated elongation (Spt6, Ssrp1) and initiation (TFIID, TBP, Med) factors. A 10-bp
156 smoothing window has been applied. Blue = Sense transcription, Red = Anti-sense
157 transcription. **(b)** Polymerase density of all NET-seq/prism libraries over a single gene
158 (*Srsf6*). **(c)** Boxplot comparison and schematic diagram of the reverse travelling ratio
159 among different NET-prism libraries of protein-coding genes (n = 823). Significance was
160 tested via the Wilcoxon rank test (* p< 0.01 , *** p< 2.2e⁻¹⁶, n.s. = non-significant).

161

162

163





164 **Assessment of kinetic splicing by NET-prism**

165 Transcriptional elongation rates can affect splicing outcomes suggesting the proposal of
166 the kinetic model of transcription and splicing coupling^{12,13}. Data generated by human
167 NET-seq, mNET-seq, and PRO-seq are consistent with this kinetic model^{2,4,7}.
168 Therefore, we sought to determine, via NET-prism, how transcriptional pausing is
169 facilitated by different Pol II variants and elongation factors over exon boundaries. As
170 splicing intermediates are known NET-seq contaminants due to the presence of 3'-OH
171 groups in these RNAs², we removed them from the analysis to avoid bias. Total RNA
172 Pol II, as assessed by NET-seq, in mouse ES cells showed increased pausing at exon
173 boundaries similarly to human cells² (**Fig. 3a** – Total Pol II). Application of NET-prism
174 confirmed that only the Pol II S5ph exhibited similar pausing, although less defined, at
175 the 3' Splice Site (3'SS). When we focused on the 5' Splice Site (5'SS) we identified that
176 Pol II pausing at the last nucleotides of the exon boundary was prominently absent for
177 all IPs (**Fig. 3a**). To methodically compare transcriptional pausing for the different IPs,
178 we introduced the 'Splicing Score', which derives from the Pol II density within 10
179 nucleotides around the 3'SS versus the density within 10 nucleotides around the 5'SS
180 (**Fig. 3b**). The Pol II S5ph seemed to exhibit the strongest association with
181 transcriptional splicing (present in 20.7% of total exons examined) compared to the
182 other libraries (Pol II S2ph; 15%, Ssrp1; 13.3%, Spt6: 5.8%) (**Fig. 3c**). In addition,
183 components of the PIC did not associate with Pol II pausing over spliced sites
184 (**Supplementary Fig. 6**). This is in agreement with previous reports that support the
185 involvement of Pol II S5ph⁷ and Ssrp1^{8,14} in the regulation of the transcriptional
186 machinery during splicing. Our data therefore suggest that transcriptional splicing

187 mechanics is facilitated by Pol II variants and elongation factors differently. At present it
188 is not clear why the phosphorylated Pol II isoforms and elongation factor IPs show
189 different occupancies in comparison with total Pol II. It is however tempting to speculate
190 that this represents some form of regulation for splicing catalysis. We also envision that
191 NET-prism might be particularly useful to address the interplay of splicing factors with
192 RNA Pol II at splice sites.

193

194



196 **Figure 3:** Association of different proteins with transcriptional splicing as assessed by
197 NET-prism. **(a)** Heatmaps and metaplots assessing polymerase pausing for total Pol II,
198 Pol II S2ph, Pol II S5ph, Ssrp1, and Spt6 over exon boundaries (n = 2,586). Solid lines
199 indicate the mean values, whereas the shading represents the 95% confidence interval.
200 **(b)** Schematic diagram depicting the calculation of the splicing score. Boxes denote the
201 10 nucleotide window around the 3'SS (blue) or 5'SS (red). **(c)** Cumulative distribution
202 of the splicing score for each NET-prism library over all the assessed exons in **(a)**.

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220



221 **Diverse enrichment of RNA Pol II over enhancer regions**

222 Enhancers and super-enhancers have been shown to play a prominent role in the
223 control of gene expression programs essential for cell identity across many mammalian
224 cell types ¹⁵. Production of enhancer RNAs (eRNAs) is bidirectional and is governed by
225 distinctive patterns of chromatin accessibility ¹⁶ but it is not well characterised whether
226 the same transcriptional rules apply over enhancers as in promoters, in terms of
227 initiation and elongation. We therefore extended our analysis over distal and super-
228 enhancers and interrogated NET-prism density. Highest correlations were identified
229 among Pol II S5ph – Ssrp1 and Pol II S2ph – Spt6 both for distal and super-enhancers
230 **(Fig. 4a)**. All Pol II variants and TFs exhibited significantly higher ChIP-seq density over
231 super-enhancers as opposed to distal enhancers. Significantly increased transcriptional
232 activity was confirmed over super-enhancers via NET-prism suggesting TF density
233 being proportional to the degree of Pol II recruitment **(Fig. 4b)**. Strikingly, both metaplot
234 profiling **(Supplementary Fig. 7)** and single enhancer **(Fig. 4c)** interrogation of NET-
235 prism transcriptional activity exposed distinctive topographic footprints; Pol II S5ph and
236 Ssrp1 displayed patterns similar to transcriptional initiation whereas Pol II S2ph and
237 Spt6 imitated a trail reminiscent of transcriptional elongation. Moreover, transcriptional
238 activity prompted by TFIID also supports, to some degree, a notion of transcriptional
239 initiation over enhancers **(Fig. 4c)**.

240

241

242



244 **Figure 4:** Distinctive patterns of transcriptional regulation over enhancers and super-
245 enhancers. **(a)** Pearson's correlation heatmap among NET-seq/prism libraries over
246 distal enhancers (blue – red) and super-enhancers (grey – gold). **(b)** Boxplots assessing
247 either transcription factor (ChIP-seq) and Pol II (NET-prism) density over distal
248 enhancers (red) and super-enhancers (gold). Significance was tested via the Wilcoxon
249 rank test (** $p < 1.0e^{-10}$, *** $p < 2.2e^{-16}$). **(c)** Pol II distribution over a distal (chr1:
250 86,484,171 – 86,495,700) or super-enhancer as assessed by NET-seq/prism. H3K27Ac
251 density is depicted in black colour. Blue and red depict RNA Pol II pausing in the
252 positive and negative strand, respectively.

253

254

255 Discussion

256 Here, we have developed a new approach to accurately assess transcriptional
257 topography at a high resolution. In summary, NET-prism allows the direct strand-
258 specific interrogation of the transcriptional landscape at single nucleotide resolution of
259 any protein of interest in complex with RNA Pol II. Its robustness enables a deeper
260 insight into the interplay of transcriptional mechanisms conferred by different Pol II
261 variants and proteins that are bound to Pol II. The comprehensive Pol II - protein
262 interactome that we provide here facilitates the choice of the protein of interest when
263 applying NET-prism. In addition, given the right RNA polymerase inhibitors and
264 antibodies, NET-prism can be extended to specifically interrogate nascent transcription
265 governed by either RNA Pol I or Pol III.

266 Although our approach relies on the release of Pol II from chromatin, NET-prism yields
267 very similar results to NET-seq as the potency of the DNase is capable of liberating Pol
268 II from all active genes (**Supplementary Fig. 8**).

269 Similarly to the human NET-seq², we expect the adaptation of NET-prism to be equally
270 straightforward in any higher eukaryotic cell type. The combination of NET-prism with a
271 high resolution ChIP-seq technique, such as ChIP-nexus¹⁷, can illuminate how exactly
272 *in vivo* binding of transcription factors correlates with transcriptional activity over
273 different cell states and conditions. Therefore, NET-prism could become a valuable tool
274 for unravelling unspecified transcriptional and regulatory complexity.

275

276

277 **Author Contributions**

278 C.M. and P.T. designed the study, C.M. performed all experiments and analysed data, C.M. and
279 P.T. interpreted results and wrote the manuscript.

280

281 **Acknowledgments**

282 We would like to thank Stirling Churchman for critical reading and comments. We are also
283 particularly grateful to Ilian Atanassov of the Max Planck Institute for Biology of Ageing
284 Proteomics Core Facility for Mass Spectrometry Analysis. Sequencing was performed at the
285 Max Planck Genome core centre in Cologne and data analysis was done on servers of the
286 GWDG, Göttingen and the MPI-AGE cluster. We thank members of the Tessarz laboratory for
287 discussion and comments on the manuscript. This work was funded by the Max Planck Society.

288

289

290 **References**

- 291 1. Churchman, L. S. & Weissman, J. S. Nascent transcript sequencing visualizes transcription at
292 nucleotide resolution. *Nature* **469**, 368–373 (2011).
- 293 2. Mayer, A. *et al.* Native elongating transcript sequencing reveals human transcriptional activity at
294 nucleotide resolution. *Cell* **161**, 541–544 (2015).
- 295 3. Min, I. M. *et al.* Regulating RNA polymerase pausing and transcription elongation in embryonic
296 stem cells. *Genes Dev.* **25**, 742–754 (2011).
- 297 4. Kwak, H., Fuda, N. J., Core, L. J. & Lis, J. T. Precise Maps of RNA Polymerase Reveal How
298 Promoters Direct Initiation and Pausing. *Science (80-)*. **339**, 950 LP-953 (2013).
- 299 5. Scruggs, B. S. *et al.* Bidirectional Transcription Arises from Two Distinct Hubs of Transcription
300 Factor Binding and Active Chromatin. *Mol. Cell* **58**, 1101–1112 (2015).
- 301 6. Fischl, H., Howe, F. S., Furger, A. & Mellor, J. Paf1 Has Distinct Roles in Transcription Elongation

- 302 and Differential Transcript Fate. *Mol. Cell* **65**, 685–698.e8 (2017).
- 303 7. Nojima, T. *et al.* Mammalian NET-seq reveals genome-wide nascent transcription coupled to RNA
304 processing. *Cell* **161**, 526–540 (2015).
- 305 8. Mylonas, C. & Tessarz, P. The repressive and alleviating nature of FACT shapes the
306 transcriptional landscape in ES cells. *In Revision*. (2018).
- 307 9. Wang, A. H. *et al.* The Elongation Factor Spt6 Maintains ESC Pluripotency by Controlling Super-
308 Enhancers and Counteracting Polycomb Proteins. *Mol. Cell* **68**, 398–413.e6 (2017).
- 309 10. Sun, M., Lariviere, L., Dengl, S., Mayer, A. & Cramer, P. A tandem SH2 domain in transcription
310 elongation factor Spt6 binds the phosphorylated RNA polymerase II C-terminal repeat domain
311 (CTD). *J. Biol. Chem.* **285**, 41597–41603 (2010).
- 312 11. Yoh, S. M., Cho, H., Pickle, L., Evans, R. M. & Jones, K. A. The Spt6 SH2 domain binds Ser2-P
313 RNAPII to direct lws1-dependent mRNA splicing and export. *Genes Dev.* **21**, 160–174 (2007).
- 314 12. Dujardin, G. *et al.* How Slow RNA Polymerase II Elongation Favors Alternative Exon Skipping.
315 *Mol. Cell* **54**, 683–690 (2014).
- 316 13. Fong, N. *et al.* Pre-mRNA splicing is facilitated by an optimal RNA polymerase II elongation rate.
317 *Genes & Development* **28**, 2663–2676 (2014).
- 318 14. Sims, R. J. *et al.* Recognition of Trimethylated Histone H3 Lysine 4 Facilitates the Recruitment of
319 Transcription Postinitiation Factors and Pre-mRNA Splicing. *Mol. Cell* **28**, 665–676 (2007).
- 320 15. Whyte, W. A. *et al.* Master transcription factors and mediator establish super-enhancers at key cell
321 identity genes. *Cell* **153**, 307–319 (2013).
- 322 16. Core, L. J. *et al.* Analysis of nascent RNA identifies a unified architecture of initiation regions at
323 mammalian promoters and enhancers. *Nat. Genet.* **46**, 1311–1320 (2014).
- 324 17. He, Q., Johnston, J. & Zeitlinger, J. CHIP-nexus enables improved detection of in vivo transcription
325 factor binding footprints. *Nat. Biotechnol.* **33**, 395–401 (2015).

326

327